OncoGenex Technologies Inc.
400 - 1001 West Broadway
Vancouver
B.C.
V6H 4B1
Canada
Tel: 604-736-3678
Fax: 604-736-3687
Website: http://www.oncogenex.ca/
23 articles about OncoGenex Technologies Inc.
-
FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011
8/22/2008
-
Sonus Pharmaceuticals, Inc. and OncoGenex Technologies Inc. Complete Business Combination
8/21/2008
-
Sonus Pharmaceuticals, Inc.'s Stockholders Approve Business Combination With OncoGenex Technologies Inc.
8/20/2008
-
OncoGenex Technologies Inc. Receives Completed Special Protocol Assessment for Primary Registration Study of Lead Drug Candidate OGX-011
7/14/2008
-
OncoGenex Technologies Inc. Increases Economic Interest in Lead Cancer Drug OGX-011
7/3/2008
-
OncoGenex Technologies Inc. Reports That Low Serum Clusterin Levels Were Predictive Of Survival In Preliminary Analyses Of Phase 2 Study Of Lead Drug Candidate OGX-011 Encouraging Survival Duration Continues With OGX-011 Plus Second-Line Chemotherapy For
6/2/2008
-
Isis Pharmaceuticals, Inc.' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology
6/2/2008
-
Sonus Pharmaceuticals, Inc. and OncoGenex Technologies Inc. to Merge
5/28/2008
-
OncoGenex Technologies Inc. Reports Updated Survival Data on OGX-011 in a Second-line Chemotherapy Trial for Patients with Prostate Cancer Updated Data to be Presented at the 2008 Annual Meeting of the American Society of Clinical Oncology
5/16/2008
-
OncoGenex Technologies Inc. Reports Lead Drug Candidate OGX-011 Achieved Primary Endpoint in Phase 2 Trial
2/15/2008
-
OncoGenex Technologies Inc. Initiates Phase I Clinical Trial of OGX-427 in Cancer
8/1/2007
-
OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. Report Encouraging Interim Phase II Data in Advanced Prostate Cancer, Affirm Phase III Clinical Trial Plans
7/31/2007
-
OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. Study Presented at American Society of Clinical Oncology Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer
6/4/2007
-
OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. Announce OGX-011 Data to be Presented at American Society of Clinical Oncology
5/31/2007
-
The Day In Review: Hollis-Eden Pharmaceuticals Inc. Loses Stockpile Contract For Neumune
3/8/2007
-
OncoGenex Technologies Inc. Withdraws Initial Public Offering
3/8/2007
-
OncoGenex Technologies Inc. Cuts IPO to $7.50-$8.50 Per Share
3/1/2007
-
The Day In Review: Will Sanofi-Aventis (France) Merge With Bristol-Myers Squibb Company?
1/30/2007
-
OncoGenex Technologies Inc. (Jobs) Sets IPO At 4.5 Million Shares, $10-$12 Each
1/29/2007
-
Canada's OncoGenex Technologies Inc. Files For $48 Million IPO
12/14/2006